

癌症類別	大腸直腸癌
Neoadjuvant CCRT	only for CCRT , for “local” rectal cancer : (1) 5-FU 425 mg/m ² (N/S 500 c.c.; 4hrs)+ Leucovorin 100 mg (N/S 500 c.c.; 4hrs) /wk (JCO 1986; 4: 685-96) (2) UFUR 900-1100 mg/ m ² /d + Leucovorin(P.O.) 30 mg/d
Neoadjuvant	Neoadjuvant C/T for colon cancer with invasion of adjacent structures : (1)(5-FU 1300 mg /m ² /d + LV 200 mg/m ² /d) N/S 500 c.c./d C.I. 2 days q 2wks (JCO 1997; 15: 808-15) (2)5-FU 600 mg /m ² (N/S 500 c.c. ; ≥3hrs) + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk (JCO 1989; 7: 1407-17) (3)UFUR 900-1100 mg/m ² /d + LV(P.O.) 30mg/d (4)(自費)Oxaliplatin 85 mg / m ² (D5W 500 c.c.; ≥ 3 hrs)+ 5-FU / LV (劑量同上) q 2wks (或以 UFUR/LV (dose 同上) 或 Capecitabine 1250-1500 mg/ m ² /d (2:1 or 5:2) 替代 V.5-FU) (Eur J.Cancer 1995; 31(S5))
Adjuvant	(I) Colorectal cancer , T ≥ subserosa or pericorectal tissues 且 LN(-) : (1)(5-FU 1300 mg /m ² /d + LV 200 mg/m ² /d) N/S 500 c.c./d C.I. 2 days q 2wks×12 doses (JCO 1997; 15: 808-15) (2)5-FU 600 mg /m ² (N/S 500 c.c. ; ≥3hrs) + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 24 doses (JCO 1989; 7: 1407-17) (3)UFUR 900-1100 mg/m ² /d + LV(P.O.) 30mg/d × 6 months (使用期限可依健保給付規定 ; ≤ 2 years)(94/10/1 、 97/12/1 健保條例 9.11) (II) Colorectal cancer , stage III : (1)(5-FU 1300mg /m ² /d + LV 200 mg/m ² /d) N/S 500 c.c./d C.I. 2 days q 2wks × 24 doses (2)5-FU 600 mg /m ² + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 48 doses (3)UFUR 900-1100 mg/m ² /d + LV(P.O.) 30mg/d × 12 months (使用期限可依健保給付規定; for stage II, III only, ≤ 2 years)(94/10/1 、 97/12/1 健保條例 9.11) (4)Capecitabine 1250-1500 mg/ m ² /d (2:1 or 5:2) × 6 months (Oncology Jan. 02, 2001) (使用期限可依健保給付規定 ; for stage III ; ≤ 8 months)(96/9/1 健保條例 9.17) (5)Oxaliplatin 85 mg / m ² (D5W 500 c.c.; ≥ 3 hrs)+ 5-FU / LV (劑量同上) q 2wks x 12 doses

	(或以 UFUR/LV (dose 同上) 或 Capecitabine (dose 同上)替代 V.5-FU) (Eur J.Cancer 1995; 31(S5)) (III)M0,anyT or N with high risk(s) : (1)(5-FU 1300mg /m²/d + LV 200 mg/m²/d) N/S 500 c.c./d C.I. 2 days q 2wks × 24 doses (2) 5-FU 600 mg /m² + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 48 doses (3) UFUR 900-1100 mg/m²/d + LV(P.O.) 30mg/d × 12 months (使用期限可依健保給付規定; ≤ 2 years)(94/10/1、97/12/1 健保條例 9.11) (4) Capecitabine 1250-1500 mg/ m²/d (2:1 or 5:2) × 6 months (Oncology Jan. 02, 2001) (使用期限可依健保給付規定; for stage III ; ≤ 8 months)(96/9/1 健保條例 9.17) (5) Oxaliplatin 85 mg / m² (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV (劑量同上) q 2wks x 12 doses (或以 UFUR/LV (dose 同上) 或 Capecitabine (dose 同上)替代 V.5-FU) (Eur J.Cancer 1995; 31(S5)) ★High risk factors : poorly differentiated carcinoma、lymphatic/vascular invasion、perineural invasion、 (near)bowel obstruction、bowel perforation、invasion of visceral peritoneum or adjacent tissue、≤11 lymph nodes sampled、margin positive or close (≤ 1mm)。
Palliative	Colorectal cancer , Stage IV : (1)(5-FU 1300 mg /m²/d + LV 200 mg/m²/d) N/S 500 c.c./d C.I. 2 days q 2wks(JCO 1997; 15: 808-15) (2)5-FU 600 mg /m² + LV 100 mg (N/S 500 c.c. ; ≥3hrs) qwk(JCO 1989; 7: 1407-17) (3)UFUR 900-1100 mg/m²/d + LV(P.O.) 30mg/d (4)Capecitabine 1250-1500 mg/ m²/d (2:1 or 5:2)(Oncology Jan. 02, 2001) (5)Oxaliplatin 85 mg / m² (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV(劑量同 Adjuvant) q2wks (或以 UFUR/LV (dose 同上)或 Capecitabine (dose 同上)替代 V.5-FU) (Cancer Treat Rev. 2006 Nov; 32 (7): 491-503) (6)Irinotecan 140,150,160 mg/ m² (N/S 500 c.c. ; 3 hrs)+5-FU / LV (劑量同 Adjuvant) q2wks (或以 UFUR/LV (dose 同上)或 Capecitabine (dose 同上)替代 V.5-FU) (7)Bevacizumab 5mg/kg/dose (N/S 100 c.c. ; 20 mins) (健保條例:可合併(1)~(6))(108/3/1 健保條例 9.37) (8)Ramucirumab 8 mg/kg/dose (N/S 300 c.c. ; 90 mins)(自費) (9)Cetuximab 250 mg/m²/dose (2 hrs) (健保條例:可合併(5)或(6))(101/12/1、104/11/1、106/1/1、110/6/1、113/6/1 健保條例 9.27) (10)Panitumumab 6 mg/kg/dose (N/S 100 c.c.; 2 hrs) (健保條例:可合併(5)或(6))(98/8/1、110/6/1、113/6/1 健保條例 9.53) (11)Regorafenib 160 mg/d (3:1) (110/6/1、113/6/1 健保條例 9.51) (12)(自費)Tegafur & Gimeracil & Oteracil (TS-1) (2:1) :

BSA < 1.25 m² : 40 mg bid ;
BSA : 1.25-1.5 m² : 50 mg bid ;
BSA ≥ 1.5 m² : 60 mg bid ;
(ASCO Jun 6, 2013)

(13) Lonsurf 35 mg/ m² bid (D1~5,D8~12) / q 28d(107/12/1、109/12/1、110/6/1、113/6/1 健保條例 9.66)

(14) Pembrolizumab 200mg q 3 wks (114/6/1 健保條例 9.69)

Immunotherapy: PD-1, PD-L1 抑制劑 (如 atezolizumab、nivolumab、Pembrolizumab、ipilimumab；durvalumab；tremelimumab)
(109/06/01 健保條例 9.69)